Kratom (Mitragyna speciosa korth) is a tropical tree from Southeast Asia. Its leaves contain chemicals that can have mind-altering effects. In the U.S., kratom is sometimes marketed as a dietary supplement, but it’s often sold as a legal herbal drug in powder and capsule forms. It also can be prepared as a tea (the traditional method) or as an extract in some other liquid. Some people use it as an alternative treatment for conditions such as pain, anxiety, depression, and opioid use disorder. However, at this time, there are no FDA-approved uses of kratom.


Military Service Members are prohibited from using any product containing kratom, given its safety concerns. Kratom is on the OPSS list of DoD-prohibited substances.


Is kratom safe to use?

Kratom has numerous side effects, including nausea, vomiting, constipation, tremors, drowsiness, fatigue, insomnia, loss of sex drive, frequent urination, seizures, tachycardia (abnormally rapid heart rate), hallucinations, liver damage, and death. Kratom has also been found to be contaminated with opioids (such as hydrocodone, fentanyl, and O-desmethyltramadol), heroin, benzodiazepines, cocaine, heavy metals, and salmonella. One potent opioid-like chemical, 7-hydroxymitragynine, is present naturally in kratom at very low levels, but some kratom products have been found to contain much higher levels of this chemical than occurs in kratom naturally. This suggests a synthetic form of this chemical has been added to these products.

Kratom can be addictive. People using kratom might experience withdrawal symptoms such as muscle aches, insomnia, irritability, hostility, aggression, and jerky movements. Infants whose mothers use kratom during pregnancy also can become addicted, a condition known as kratom-associated neonatal abstinence syndrome.

Is kratom a controlled substance?

Currently, kratom is not a controlled substance, although the U.S. Drug Enforcement Agency (DEA) considers it a “drug of concern.” In countries where it is grown, it is chewed or made into a tea to counteract fatigue or reduce anxiety. The dose is important. At low doses it acts as a stimulant, but at higher doses it has opioid-like and psychoactive effects, which encourage its use as a recreational substance. However, it might also have potential therapeutic uses, and many users self-medicate with kratom to relieve opioid withdrawal symptoms, heroin and morphine addiction, and chronic pain. The conflict between the potential for abuse and this potential for therapeutic use has put a halt so far to making kratom a controlled substance. At this time, it is readily available online.

Federal agencies continue to investigate the effects of kratom, and DEA is still considering classifying the two major active substances in kratom—mitragynine and 7-hydroxymitragynine—as Schedule I controlled substances. For now, a number of states and cities have banned its use, and it is illegal in several countries, including those in which the plant is grown: Thailand, Malaysia, Myanmar, and Australia.

What is FDA’s stance on kratom?

FDA warns consumers not to use kratom. According to FDA:

  • Kratom is not approved for use in dietary supplements. “FDA has exercised jurisdiction over kratom as an unapproved drug, and has also taken action against kratom-containing dietary supplements.”
  • Kratom often is marketed as a “safe” treatment for some serious health conditions, but kratom contains compounds that “make it so it isn’t just a plant – it’s an opioid.”
  • FDA has concerns about “kratom’s potential for abuse, addiction, and serious health consequences; including death.” In fact, there has been an increase in reported deaths associated with kratom use since November 2017.
  • FDA has a well-developed process for evaluating botanical drug products, but “To date, no marketer has sought to properly develop a drug that includes kratom.”

Will kratom affect a drug test?

Kratom use will not produce a positive result on a routine DoD drug test. Regardless, Military Service Members are prohibited from using any product containing kratom, given its safety concerns. Kratom is on the OPSS list of DoD-prohibited substances.

For more information about kratom, please see:

 

Updated 7 May 2020

References

Ahmad, K., & Aziz, Z. (2012). Mitragyna speciosa use in the northern states of Malaysia: A cross-sectional study. Journal of Ethnopharmacology, 141(1), 446–450. doi:10.1016/j.jep.2012.03.009

Alsarraf, E., Myers, J., Culbreth, S., & Fanikos, J. (2019). Kratom from head to toe—case reviews of adverse events and toxicities. Current Emergency and Hospital Medicine Reports, 7(4), 141–168. doi:10.1007/s40138-019-00194-1

Brown, P. N., Lund, J. A., & Murch, S. J. (2017). A botanical, phytochemical and ethnomedicinal review of the genus Mitragyna korth: Implications for products sold as kratom. Journal of Ethnopharmacology, 202, 302–325. doi:10.1016/j.jep.2017.03.020

Colucci, S., Culbreth, S., Alsarraf, E., & Fanikos, J. (2019). Why does the Food and Drug Administration need to ban kratom? Current Emergency and Hospital Medicine Reports, 7(4), 169–174. doi:10.1007/s40138-019-00201-5

Corkery, J. M., Streete, P., Claridge, H., Goodair, C., Papanti, D., Orsolini, L., . . . Hendricks, A. (2019). Characteristics of deaths associated with kratom use. Journal of Psychopharmacology, 33(9), 1102–1123. doi:10.1177/0269881119862530

Davidson, L., Rawat, M., Stojanovski, S., & Chandrasekharan, P. (2019). Natural drugs, not so natural effects: Neonatal abstinence syndrome secondary to ‘kratom’. Journal of Neonatal-Perinatal Medicine, 12(1), 109–112. doi:10.3233/npm-1863

Eastlack, S. C., Cornett, E. M., & Kaye, A. D. (2020). Kratom—Pharmacology, clinical implications, and outlook: A comprehensive review. Pain and Therapy, 1–25. doi:10.1007/s40122-020-00151-x

Eldridge, W. B., Foster, C., & Wyble, L. (2018). Neonatal abstinence syndrome due to maternal kratom use. Pediatrics, 142(6), Article e20181839. doi:10.1542/peds.2018-1839

Garcia-Romeu, A., Cox, D. J., Smith, K. E., Dunn, K. E., & Griffiths, R. R. (2020). Kratom (Mitragyna speciosa): User demographics, use patterns, and implications for the opioid epidemic. Drug and Alcohol Dependence, 208, article 107849. doi:10.1016/j.drugalcdep.2020.107849

Gauvin, D. V., & Zimmermann, Z. J. (2018). A reply to Henningfield, Fant & Wang (2018): Regulatory action to control kratom is long overdue. Psychopharmacology, 236(3), 861–863. doi:10.1007/s00213-018-5112-4

Gershman, K., Timm, K., Frank, M., Lampi, L., Melamed, J., Gerona, R., & Monte, A. A. (2019). Deaths in Colorado attributed to kratom. New England Journal of Medicine, 380(1), 97–98. doi:10.1056/NEJMc1811055

Gutridge, A. M., Robins, M. T., Cassell, R. J., Uprety, R., Mores, K. L., Ko, M. J., . . . Rijn, R. M. (2019). G protein‐biased kratom‐alkaloids and synthetic carfentanil‐amide opioids as potential treatments for alcohol use disorder. British Journal of Pharmacology, Article 14913. doi:10.1111/bph.14913

Hughes, R. L. (2018). Fatal combination of mitragynine and quetiapine – a case report with discussion of a potential herb-drug interaction. Forensic Science, Medicine and Pathology, 15(1), 110–113. doi:10.1007/s12024-018-0049-9

Kruegel, A. C., Uprety, R., Grinnell, S. G., Langreck, C., Pekarskaya, E. A., Le Rouzic, V., . . . Sames, D. (2019). 7-hydroxymitragynine is an active metabolite of Mitragynine and a key mediator of its analgesic effects. ACS Central Science, 5(6), 992–1001. doi:10.1021/acscentsci.9b00141

Lovrecic, B., Lovrecic, M., Gabrovec, B., Carli, M., Pacini, M., Maremmani, A. G. I., & Maremmani, I. (2019). Non-medical use of novel synthetic opioids: A new challenge to public health. International Journal of Environmental Research and Public Health, 16(2), Article 177. doi:10.3390/ijerph16020177

Meireles, V., Rosado, T., Barroso, M., Soares, S., Gonçalves, J., Luís, Â., . . . Gallardo, E. (2019). Mitragyna speciosa: Clinical, toxicological aspects and analysis in biological and non-biological samples. Medicines, 6(1), article 35. doi:10.3390/medicines6010035

Nacca, N., Schult, R. F., Li, L., Spink, D. C., Ginsberg, G., Navarette, K., & Marraffa, J. (2019). Kratom adulterated with phenylethylamine and associated intracerebral hemorrhage: Linking toxicologists and public health officials to identify dangerous adulterants. Journal of Medical Toxicology, 16(1), 71–74. doi:10.1007/s13181-019-00741-y

Nellhaus, E., Andrews, L., Haas, J., Miskell, D., Kurek, K., Hansen, Z., & Davies, T. H. (2018). Neonatal withdrawal following in utero exposure to kratom. International Journal of Clinical Pediatrics, 7(4), 55–58. doi:10.14740/ijcp317w

Olsen, E. O. M., O’Donnell, J., Mattson, C. L., Schier, J. G., & Wilson, N. (2019). Notes from the Field: Unintentional drug overdose deaths with kratom detected — 27 states, July 2016–December 2017. MMWR. Morbidity and Mortality Weekly Report, 68(14), 326–327. doi:10.15585/mmwr.mm6814a2

Osborne, C. S., Overstreet, A. N., Rockey, D. C., & Schreiner, A. D. (2019). Drug-induced liver injury caused by kratom use as an alternative pain treatment amid an ongoing opioid epidemic. Journal of Investigative Medicine High Impact Case Reports, 7, Article 232470961982616. doi:10.1177/2324709619826167

Overbeek, D., Abraham, J., & Munzer, B. (2019). Kratom (mitragynine) ingestion requiring naloxone reversal. Clinical Practice and Cases in Emergency Medicine, 3(1), 24–26. doi:10.5811/cpcem.2018.11.40588

Prozialeck, W. C., Avery, B. A., Boyer, E. W., Grundmann, O., Henningfield, J. E., Kruegel, A. C., . . . Singh, D. (2019). Kratom policy: The challenge of balancing therapeutic potential with public safety. International Journal of Drug Policy, 70, 70–77. doi:10.1016/j.drugpo.2019.05.003

Raffa, R. B., Pergolizzi, J. V., Taylor, R., & Ossipov, M. H. (2018). Nature's first “atypical opioids”: Kratom and mitragynines. Journal of Clinical Pharmacy and Therapeutics, 43(3), 437–441. doi:10.1111/jcpt.12676

Ramachandram, D. S., Damodaran, T., Zainal, H., Murugaiyah, V., & Ramanathan, S. (2019). Pharmacokinetics and pharmacodynamics of mitragynine, the principle alkaloid of Mitragyna speciosa: Present knowledge and future directions in perspective of pain. Journal of Basic and Clinical Physiology and Pharmacology, 31(1), article 0138. doi:10.1515/jbcpp-2019-0138

Ratard, R. (2019). Kratom (Mitragyna speciose) Study: On the Public Health Risks and Recommendations. Bureau of Infectious Diseases, Infectious Disease and Epidemiology, Office of Public Health, Louisiana Department of Health, http://www.ldh.la.gov/assets/docs/LegisReports/HR177RS2018219.pdf

Rybarczyk, K. S. (2019). Quantitative analysis of Mitragynine in consumer products labeled as kratom. (M.S.), University of Illinois at Chicago, Chicago, Illinois. Retrieved from https://search.proquest.com/openview/3705304cf2ba705ad2791c58ea9d47a4/1.pdf?pq-origsite=gscholar&cbl=18750&diss=y

Singh, D., Damodaran, T., Prozialeck, W. C., Grundmann, O., Karunakaran, T., & Vicknasingam, B. (2018). Constipation prevalence and fatigue severity in regular kratom (Mitragyna speciosa Korth.) users. Journal of Substance Use, 24(3), 233–239. doi:10.1080/14659891.2018.1546340

Smith, K. E., Bunting, A. M., Walker, R., Hall, M. T., Grundmann, O., & Castillo, O. (2019). Non-prescribed buprenorphine use mediates the relationship between heroin use and kratom use among a sample of polysubstance users. Journal of Psychoactive Drugs, 51(4), 311–322. doi:10.1080/02791072.2019.1597224

Spetea, M., & Schmidhammer, H. (2019). Unveiling 7-hydroxymitragynine as the key active metabolite of mitragynine and the promise for creating novel pain relievers. ACS Central Science, 5(6), 936–938. doi:10.1021/acscentsci.9b00462

Stanciu, C. N., Gnanasegaram, S. A., Ahmed, S., & Penders, T. (2019). Kratom withdrawal: A systematic review with case series. Journal of Psychoactive Drugs, 51(1), 12–18. doi:10.1080/02791072.2018.1562133

Suhaimi, F. W., Yusoff, N. H. M., Hassan, R., Mansor, S. M., Navaratnam, V., Müller, C. P., & Hassan, Z. (2016). Neurobiology of kratom and its main alkaloid mitragynine. Brain Research Bulletin, 126, 29–40. doi:10.1016/j.brainresbull.2016.03.015

Tatum, W. O., Hasan, T. F., Coonan, E. E., & Smelick, C. P. (2018). Recurrent seizures from chronic kratom use, an atypical herbal opioid. Epilepsy & Behavior Case Reports, 10, 18–20. doi:10.1016/j.ebcr.2018.04.002

Tayabali, K., Bolzon, C., Foster, P., Patel, J., & Kalim, M. O. (2018). Kratom: A dangerous player in the opioid crisis. Journal of Community Hospital Internal Medicine Perspectives, 8(3), 107–110. doi:10.1080/20009666.2018.1468693

Veltri, C., & Grundmann, O. (2019). Current perspectives on the impact of Kratom use. Substance Abuse and Rehabilitation, Volume 10, 23–31. doi:10.2147/sar.S164261

Webb1, M., Isenschmid, D. S., Sung, L., Hlavaty, L., & Gupta, A. (2019). Kratom: The herbal opioid. Journal of Clinical Toxicology, 9(4), article 1000422.  Retrieved from https://www.longdom.org/open-access/kratom-the-herbal-opioid.pdf